The FDA Peptide Vote: What Actually Happened This Week
If your feed has been full of headlines saying the FDA just “approved peptides,” here’s the more accurate, and honestly more interesting, version of what happened this week.
What actually happened
On July 23 and 24, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) met to vote on seven peptides being considered for addition to the agency’s list of bulk drug substances that specialty compounding pharmacies are legally allowed to use. That’s a specific, technical thing. It’s not the same as the FDA approving a drug for sale at a regular pharmacy. More on that distinction below, because it matters.
Here’s how the votes broke down:
- BPC-157: recommended, 8-6 with one abstention
- KPV: recommended, 8-6 with one abstention
- TB-500: recommended
- MOTS-c: recommended
- Epitalon: recommended, 7-5 with one abstention
- Semax: recommended
- Emideltide: rejected, 6-7 with one abstention
Six of the seven got a thumbs-up. Only emideltide, a compound we don’t have a page on yet, was voted down.
Why this isn’t “FDA approval”
This is the part that’s easy to miss in a scrolling headline. The vote wasn’t about whether any of these peptides are safe and effective enough to be sold as approved drugs. That’s a completely different, much longer FDA process. This vote was narrowly about Section 503A of the Food, Drug & Cosmetic Act, which governs what raw ingredients licensed compounding pharmacies can legally use to make custom preparations for individual patients.
In plain terms: a “yes” vote here means a compounding pharmacy could potentially source and dispense that peptide legally, under a prescription, without it being an FDA-approved drug in the normal sense. It’s a meaningfully different bar than approval: lower in some ways, since it doesn’t require the same clinical trial evidence, but still a real regulatory gate that’s been closed for these compounds until now.
Why it’s controversial
This wasn’t a rubber-stamp vote. FDA staff scientists reportedly recommended against adding any of the seven peptides, citing a lack of solid clinical trial data, batch-to-batch inconsistency in how compounded peptides are actually made, and the risk of triggering immune reactions. The committee went against its own agency’s staff recommendation, which multiple outlets pointed out is unusual. Reporting from NBC News also noted that several panel members who voted yes have ties to the peptide industry, which added another layer to the debate.
The vote itself is nonbinding. The FDA makes the final call, and there’s no announced timeline yet for when that decision will come.
What this means right now
Nothing has changed today. These six peptides aren’t newly approved, legal-everywhere products as of this vote. The FDA still has to act on the recommendation, and even if it does, this only affects what licensed compounding pharmacies can use, not general availability. If you’re following this space, this is a step worth knowing about, not a finish line.
For background on the individual compounds involved, we’ve got pages on BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax.
Sources:
- FDA advisers vote to ease peptide restrictions, despite agency concerns (NPR)
- In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides (STAT News)
- FDA panel, with ties to the peptide industry, recommends easing restrictions on four of the compounds (NBC News)
- FDA advisory committee backs two more peptides, rejects one for compounding list (RAPS)